Analyst Price Target is $50.63
▲ +557.47% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $50.63, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 557.47% upside from the last price of $7.70.
Current Consensus is
The current consensus among 8 polled investment analysts is to buy stock in Protagonist Therapeutics. This Buy consensus rating has held steady for over two years.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.